www.absoricald-hcp.com
Open in
urlscan Pro
151.101.195.10
Public Scan
URL:
https://www.absoricald-hcp.com/?utm_source=BioPharm&utm_medium=Email&utm_campaign=981871&utm_content=PM-US-ABD-0438
Submission: On May 12 via api from US — Scanned from DE
Submission: On May 12 via api from US — Scanned from DE
Form analysis
0 forms found in the DOMText Content
You need to enable JavaScript to run this app. You are about to leave ABSORICALD-HCP.com. Click OK to continue or cancel to return OKCancel You are about to leave ABSORICALD-HCP.com. Click OK to continue or cancel to return OKCancel You are about to leave ABSORICALD-HCP.com. Click OK to continue or cancel to return OKCancel * DOSING * ACCESS * LD DIFFERENCE * LONG-LASTING CLEARANCE * NO MEAL REQUIREMENTS * 2X ABSORPTION * REAL RESULTS * Important Safety Information * Prescribing Information * Medication Guide * iPLEDGE® * Contact * Patient Site PHARMACY FINDER LASTING DIFFERENCE1,2* WITH ABSORICA LD® FOR THE TREATMENT OF SEVERE RECALCITRANT NODULAR ACNE Actual ABSORICA LD Patient IMPORTANT SAFETY INFORMATION Because of the risk of embryo-fetal toxicity, ABSORICA LD is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the iPLEDGE® REMS. Please see full Important Safety Information. Low Dosing with maximal absorption1,3 Affordability Options for ALL insured patients LD Difference Long-lasting clearance with no meal requirements1-3* -------------------------------------------------------------------------------- *ABSORICA®/ABSORICA LD CLINICAL STATEMENT ABSORICA LD was approved by the FDA based on ABSORICA clinical data. Please see full Clinical Statement. REAL PATIENT RESULTS BEFORE AFTER Actual ABSORICA LD patient of Haleh Bakshandeh, MD SEE THE LD DIFFERENCE An ABSORICA LD patient story Because of the risk of embryo-fetal toxicity, ABSORICA LD is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the iPLEDGE® REMS. Please see full Important Safety Information. isi hidden ABSORICA LD OFFERS A LOW DOSE FORMULATION Learn About Dosing View allView less IMPORTANT SAFETY INFORMATION WARNING: EMBRYO-FETAL TOXICITY – CONTRAINDICATED IN PREGNANCY ABSORICA LD can cause severe life-threatening birth defects and is contraindicated in pregnancy. There is an extremely high risk that severe birth defects will result if pregnancy occurs while taking any amount of ABSORICA LD even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining prenatally whether an exposed fetus has been affected. If pregnancy occurs, discontinue ABSORICA LD immediately and refer the patient to an Obstetrician-Gynecologist experienced in reproductive toxicity for further evaluation and counseling. Because of the risk of embryo-fetal toxicity, ABSORICA LD is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the iPLEDGE® REMS. INDICATIONS AND USAGE ABSORICA LD (isotretinoin) capsules is indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, ABSORICA LD is reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. Limitations of Use: If a second course of ABSORICA LD therapy is needed, it is not recommended before a two-month waiting period because the patient’s acne may continue to improve following a 15 to 20-week course of therapy. CONTRAINDICATIONS Pregnancy: ABSORICA LD is contraindicated in pregnancy. Hypersensitivity: ABSORICA LD is contraindicated in patients with hypersensitivity to isotretinoin (or Vitamin A, given the chemical similarity to isotretinoin) or to any of its components (anaphylaxis and other allergic reactions have occurred). WARNINGS AND PRECAUTIONS ABSORICA and ABSORICA LD are Not Substitutable: The bioavailability and the recommended dosage of ABSORICA and ABSORICA LD are different. For example, while ABSORICA and ABSORICA LD both have a 20 mg strength, these strengths have different bioavailability and are not substitutable. Psychiatric Disorders: ABSORICA LD may cause depression, psychosis and, rarely, suicidal ideation, suicide attempts, suicide, and aggressive and/or violent behaviors. Prior to and during therapy, assess for these conditions. Patients should immediately stop ABSORICA LD and promptly contact their prescriber if they develop depression, mood disturbance, psychosis, or aggression. Discontinuation of ABSORICA LD may be insufficient; further evaluation may be necessary such as a referral to a mental healthcare professional. Intracranial Hypertension (Pseudotumor Cerebri): Isotretinoin use has been associated with cases of intracranial hypertension (pseudotumor cerebri), some of which involved concomitant use of tetracyclines. Concomitant treatment with tetracyclines should therefore be avoided with ABSORICA LD use. Serious Skin Reactions: There have been postmarketing reports of erythema multiforme and severe skin reactions [e.g., Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)] associated with isotretinoin use. These reactions may be serious and result in death, life-threatening events, hospitalization, or disability. Patients should be monitored closely for severe skin reactions, and ABSORICA LD should be discontinued if they occur. Acute Pancreatitis: Acute pancreatitis has been reported with isotretinoin use in patients with either elevated or normal serum triglyceride levels. In rare instances, fatal hemorrhagic pancreatitis has been reported. If symptoms of pancreatitis occur, the patient should discontinue ABSORICA LD and seek medical attention. Lipid Abnormalities: Elevations of serum triglycerides above 800 mg/dL have been reported with isotretinoin use. These lipid changes were reversible upon isotretinoin capsule cessation. Some patients have been able to reverse triglyceride elevation by reduction in weight and restriction of dietary fat and alcohol while continuing isotretinoin or through dosage reduction. The cardiovascular consequences of hypertriglyceridemia associated with isotretinoin are unknown. Hearing Impairment: Impaired hearing has been reported in patients taking isotretinoin; in some cases, the impairment has been reported to persist after therapy has been discontinued. Mechanism(s) and causality for this reaction have not been established. Patients who experience tinnitus or hearing impairment should discontinue ABSORICA LD treatment and be referred for specialized care for further evaluation. Hepatotoxicity: Clinical hepatitis has been reported with isotretinoin use. Additionally, mild to moderate elevations of liver enzymes have been observed in approximately 15% of individuals treated during clinical trials with isotretinoin capsules, some of which normalized with dosage reduction or continued administration of the drug. If normalization does not readily occur or if hepatitis is suspected during treatment, ABSORICA LD should be discontinued. Inflammatory Bowel Disease: Isotretinoin has been associated with inflammatory bowel disease (including regional ileitis) in patients without a prior history of intestinal disorders. In some instances, symptoms have been reported to persist after isotretinoin treatment has been stopped. Patients experiencing abdominal pain, rectal bleeding or severe diarrhea should discontinue ABSORICA LD immediately. Musculoskeletal Abnormalities: Effects of multiple courses of isotretinoin on the developing musculoskeletal system are unknown. There is some evidence that long-term, high-dose, or multiple courses of therapy with isotretinoin have more of an effect than a single course of therapy on the musculoskeletal system. It is important that ABSORICA LD be given at the recommended dose for no longer than the recommended duration. Ocular Abnormalities: Visual problems should be carefully monitored. If visual difficulties occur, the patient should discontinue ABSORICA LD treatment and obtain an ophthalmological examination. ADVERSE REACTIONS Most common adverse reactions (incidence ≥ 5%) are: dry lips, dry skin, back pain, dry eye, arthralgia, epistaxis, headache, nasopharyngitis, chapped lips, dermatitis, increased creatine kinase, cheilitis, musculoskeletal discomfort, upper respiratory tract infection, reduced visual acuity. DRUG INTERACTIONS Vitamin A: ABSORICA LD is closely related to vitamin A. Therefore, the use of both vitamin A and ABSORICA LD at the same time may lead to vitamin A related adverse reactions. Patients treated with ABSORICA LD should be advised against taking supplements containing Vitamin A to avoid additive toxic effects. Tetracyclines: Concomitant treatment with ABSORICA LD and tetracyclines should be avoided because isotretinoin use has been associated with a number of cases of intracranial hypertension (pseudotumor cerebri), some of which involved concomitant use of tetracyclines. USE IN SPECIFIC POPULATIONS There are no data on the presence of isotretinoin in either animal or human milk, the effects on the breastfed infant, or the effects on milk production. Because of the potential for serious adverse reactions in nursing infants from isotretinoin, advise patients that breastfeeding is not recommended during treatment with ABSORICA LD, and for at least 8 days after the last dose of ABSORICA LD. These are not all of the possible side effects of ABSORICA LD. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or Sun Pharmaceutical Industries, Inc. at 1-800-818-4555. Please see full Prescribing Information for Boxed Warning, Contraindications, and other important Warnings and Precautions. References: 1. ABSORICA/ABSORICA LD [prescribing information]. Sun Pharmaceutical Industries, Inc: November 2019. 2. Del Rosso JQ, Stein Gold L, Segal J, Zaenglein AL. An open-label, phase IV study evaluating lidose-isotretinoin administered without food in patients with severe recalcitrant nodular acne: Low relapse rates observed over the 104-week post-treatment period. J Clin Aesthet Dermatol. 2019;12(11):13-18. 3. Madan S, Kumar S, Segal J. Comparative pharmacokinetic profiles of a novel low-dose micronized isotretinoin 32 mg formulation and lidose-isotretinoin 40 mg in fed and fasted conditions: two open-label, randomized, crossover studies in healthy adult participants. Acta Derm Venereol. 2020;100(1-4):1-7. This site is intended for US residents only. ABSORICA and ABSORICA LD are trademarks of Sun Pharmaceutical Industries, Inc. All other trademarks are property of their respective owners. ©2023 Sun Dermatology, a division of Sun Pharmaceutical Industries, Inc. All rights reserved. PM-US-ABD-0483 04/23 Terms of UsePrivacy PolicyContact This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We also share information about your use of our site with our social media, advertising and analytics partners. Do Not Sell My Personal Information Accept Cookies DO NOT SELL MY PERSONAL INFORMATION * YOUR PRIVACY * STRICTLY NECESSARY COOKIES * SALE OF PERSONAL DATA YOUR PRIVACY When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link. More information STRICTLY NECESSARY COOKIES Always Active These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information. SALE OF PERSONAL DATA Sale of Personal Data Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalized ads and will not hand over your personal information to any third parties. Additionally, click here to read our Privacy Policy and for further clarification about your rights as a California consumer. If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according to your preferences. * PERFORMANCE COOKIES Switch Label label These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance. * TARGETING COOKIES Switch Label label These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising. Back Button BACK Filter Button Consent Leg.Interest checkbox label label checkbox label label checkbox label label Clear checkbox label label Apply Cancel Confirm My Choices Allow All